Psychopharmacology and Psychiatry Updates Motherhood and Medication: LAIs for Women with Schizophrenia
May 21, 2025
Oliver Freudenreich, a seasoned psychiatrist from Boston, delves into the complexities of treating women with schizophrenia using long-acting injectable antipsychotics. He highlights the impact of hormonal fluctuations, particularly during pregnancy and postpartum, on medication efficacy. The discussion also covers the unique challenges women face regarding treatment adherence and the need for personalized strategies. Freudenreich emphasizes how these tailored approaches can significantly improve stability and support for women during critical life transitions.
AI Snips
Chapters
Transcript
Episode notes
Schizophrenia Onset in Women
- Women tend to develop schizophrenia later than men, often after starting families and education.
- Women have a second onset peak during menopause linked to decreasing estrogen, impacting treatment.
LAIs Use During Pregnancy
- Consider long-acting injectables for women during pregnancy and postpartum when relapse risk and medication adherence challenges are high.
- Avoid LAIs in women at risk of preterm birth or those planning exclusive breastfeeding to manage prolactin impact.
LAIs to Protect Motherhood
- Use long-acting injectables for mothers with schizophrenia to help prevent relapse and keep custody of their children.
- Relapse prevention is vital due to social stigma and potential state intervention.